Atar, Daniel
Ruoff, Lara
Mast, Anna-Sophia
Krost, Simon http://orcid.org/0009-0000-4257-4334
Moustafa-Oglou, Moustafa
Scheuermann, Sophia
Kristmann, Beate http://orcid.org/0009-0005-8299-5316
Feige, Maximilian
Canak, Aysegül
Wolsing, Kathrin
Schlager, Lennart http://orcid.org/0009-0004-7536-0657
Schilbach, Karin http://orcid.org/0000-0001-8041-055X
Zekri, Latifa
Ebinger, Martin http://orcid.org/0000-0002-4229-8058
Nixdorf, Daniel
Subklewe, Marion http://orcid.org/0000-0001-9154-9469
Schulte, Johannes
Lengerke, Claudia http://orcid.org/0000-0001-5442-2805
Jeremias, Irmela http://orcid.org/0000-0003-1773-7677
Werchau, Niels
Mittelstaet, Joerg
Lang, Peter
Handgretinger, Rupert
Schlegel, Patrick http://orcid.org/0000-0002-5425-2049
Seitz, Christian M. http://orcid.org/0000-0002-0520-7866
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (411791562, 411791562, 411791562)
Article History
Received: 30 January 2024
Revised: 14 June 2024
Accepted: 9 July 2024
First Online: 3 August 2024
Competing interests
: The employing institution of DA, LR, ASM, SK, MM, SS, BK, MF, AC, KW, KS, ME, JS, PL, RH, and CMS (University Children’s Hospital Tuebingen) received research support from Miltenyi Biotec GmbH on the basis of a collaboration research agreement. CMS receives research funding from Miltenyi Biotec GmbH not related to the presented work. MS receives industry research support from Amgen, Bristol-Myers Squibb/Celgene, Gilead, Janssen, Miltenyi Biotec, Morphosys, Novartis, Roche, Seattle Genetics, and Takeda and serves as a consultant/advisor to AvenCell, CDR-Life, Ichnos Sciences, Incyte Biosciences, Janssen, Molecular Partners, and Takeda. She serves on the speakers’ bureau at Amgen, AstraZeneca, BMS/Celgene, Gilead, GSK, Janssen, Novartis, Pfizer, Roche, and Takeda. Furthermore, PL, RH, JM, PS and CMS are coinventors on a patent (WO2018078066A1) focusing on Adapter CAR technology. Other authors declare no relevant conflicts of interest.